The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen.

"Conflicts of interest W.D.F.V. has received speaking honoraria for pharmaceutical and managed care organizations, as well as for participation on advisory boards (all less than $1000/year). The United States Agency for International Development (USAID) invests in OPTIMIZE through its support of a global consortium, led by Wits RHI, that includes ICAP at Columbia University, Mylan Laboratories, the University of Liverpool and the Medicines Patent Pool. USAID is a key implementing agency of the US President's Emergency Plan for AIDS Relief (PEPFAR) and is responsible for over half of all PEPFAR programmes with activities focused in 35 priority countries and regions, mainly in sub-Saharan Africa and Asia. For more information, please visit:www.usaid.gov. Unitaid finds new and better ways to prevent, test and treat HIV, tuberculosis and malaria quickly and more affordably. It takes game-changing ideas and turns those into practical solutions that can help accelerate the end of the three diseases. Established in 2006 by Brazil, Chile, France, Norway and the United Kingdom, Unitaid plays an important part in the global effort to defeat HIV, tuberculosis and malaria. For more information, please visit:www.unitaid.org. ADVANCE is supported by Unitaid and the United States Agency for International Development (USAID), through the President's Emergency Plan for AIDS Relief (PEPFAR), as well as the South African Medical Research Council. Study drug has been donated by Gilead Sciences and ViiV Healthcare."

"Financial support and sponsorship The study is supported by the United States President's Emergency Plan for AIDS Relief (PEPFAR)/United States Agency for International Development (USAID) and Unitaid, as well as the South African Medical Research Council (MRC) in a broader collaboration addressing drug formulation and introduction, called OPTIMIZE. The study drug is donated by the originator companies, ViiV Healthcare (UK) and Gilead Sciences (USA)."